SleepCheck, page-88

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 88 Last

Share
Profile

Follow
Thegun96

2,084 Posts.

179

10/08/20

10:28

Post #: 46418291
Share

Originally posted by Bloky ↑

A question from the latest conference call

Our next question is from [Terry Flynn]. -------------------------------------------------------------------------------- Unidentified Analyst, [23] -------------------------------------------------------------------------------- I just wanted to check in on the SleepCheck app. Were you planning on, I suppose, reapplying to have that accredited as a diagnostic tool and not just a screening tool? -------------------------------------------------------------------------------- Anthony Keating, ResApp Health Limited - CEO, MD & Director [24] -------------------------------------------------------------------------------- So at this point, no. So at this point, we believe that as a screening tool, we have the best chance of making a larger impact in the general population. So I think you need to -- what's important to realize in that, there are 2 different opportunities in many health care situations. So one is a screening opportunity, which is screening a large number of people and identifying those people who are at risk. And then obviously, the second part, which is the diagnostics part, which is the formal diagnosis to lead to treatment. So our target with SleepCheck is the first, is to mass screen large numbers of people. That's the mass consumer market products to identify risk. And so the second part there, we may end up towards, in the longer term, moving through a diagnostic product. But we believe that the commercial opportunity today is actually the mass market. And that is map screening and identifying risk. So I would say rather than being a regulatory decision about whether it's classed as a screening tool or a diagnostic tool. It's actually a business decision. We believe that the best business opportunity here is screening -- mass screening direct-to-consumer product here

Regards
Bloky

Expand

I'm surprised Resmed etc
Have not taken a position in RAP
YET....
Times are changing and ticking away...
Could be a good Christmas.

RAP Price at posting: 14.5¢ Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

ARV

Smallcap Artemis Res' jumps 23% on six digit gold grade rockchip find at Titan

LM8

Lunnon expands gold program at KGNP in Western Australia, reports Lady Herial growth

ARB

Court process clears way for ARB to buy up 4 Wheel Parts business in the US

PAT

Patriot Lithium eyeing up Zambia-based Katawaro copper project

LEX

Lefroy boosts near-surface gold resource by 13% to 439Koz